Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

- 1. (Original) A method of inducing apoptosis in a cancer cell, the method comprising contacting the cell with:
 - i. an anti-DR4 or anti-DR5 affinity agent agonist; and
 - ii. an apoptosis-inducing agent.
- 2. (Original) The method of claim 1, wherein the agonist is an anti-DR-5 antibody.
- 3. (Original) The method of claim 2, wherein the anti-DR5 antibody has the binding specificity of an antibody comprising a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35.
- 4. (Original) The method of claim 3, wherein the anti-DR5 antibody comprises a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35.
- 5. (Original) The method of claim 2, wheren the anti-DR5 antibody is Antibody A (ATCC Deposit No. ____).
- 6. (Original) The method of claim 1, wherein the agonist is an anti-DR4 antibody.

- 7. (Original) The method of claim 1, wherein the cell is contacted with an anti-DR4 antibody agonist and an anti-DR5 antibody agonist.
- 8. (Original) The method of claim 1, wherein the agonist is a humanized antibody.
- 9. (Original) The method of claim 1, wherein the agonist is a single chain antibody.
- 10. (Original) The method of claim 1, wherein the agent prevents or reduces the expression of BCL-2.
- 11. (Original) The method of claim 10, wherein the agent prevents activation of NFκB.
- 12. (Original) The method of claim 11, wherein the agent prevents degradation of IkB.
- 13. (Original) The method of claim 1, wherein the agent is a proteasome inhibitor.
- 14. (Original) The method of claim 13, wherein the proteasome inhibitor is selected from the group consisting of PS-341, MG-262 and MG-132.
- 15. (Original) The method of claim 1, wherein the agent is an inhibitor of an Inhibitor of Apoptosis (IAP) protein.
- 16. (Original) The method of claim 15, wherein the inhibitor is SMAC or a SMAC mimetic.

- 17. (Original) The method of claim 1, wherein the cancer cell is a colon cancer cell or a pancreatic cancer cell.
- 18. (Original) The method of claim 1, wherein the agent is an antagonist of PAK1.
- 19. (Original) The method of claim 1, wherein the agent is an antagonist of a polypeptide selected from the group consisting of nsurf and JIK.
 - 20. (Original) The method of claim 1, wherein the agent is a siRNA.
- 21. (Original) A method of inducing apoptosis in a cancer cell in an individual in need thereof, the method comprising,

administering to the individual a therapeutically effective amount of

- i. an anti-DR4 or anti-DR5 affinity agent agonist; and
- ii. an apoptosis-inducing agent.
- 22. (Original) The method of claim 21, wherein the agonist and the agent are administered separately.
- 23. (Original) The method of claim 21, wherein the agonist and the agent are administered as a mixture.
- 24. (Original) The method of claim 21, wherein the agonist is an anti-DR-5 antibody.
- 25. (Original) The method of claim 24, wherein the anti-DR5 antibody has the binding specificity of an antibody comprising a heavy chain variable region comprising the

sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35.

- 26. (Original) The method of claim 25, wherein the anti-DR5 antibody comprises a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35.
- 27. (Original) The method of claim 25, wherein the anti-DR5 antibody is Antibody A (ATCC Deposit No. _____).
- 28. (Original) The method of claim 21, wherein the agonist is an anti-DR4 antibody.
- 29. (Original) The method of claim 21, wherein the cell is contacted with an anti-DR4 antibody agonist and an anti-DR5 antibody agonist.
- 30. (Original) The method of claim 21, wherein the agonist is a humanized antibody.
- 31. (Original) The method of claim 21, wherein the agonist is a single chain antibody.
- 32. (Original) The method of claim 21, wherein the agent prevents or reduces the expression of BCL-2 or UbcH10.
- 33. (Original) The method of claim 32, wherein the agent prevents activation of NFκB.

- 34. (Original) The method of claim 33, wherein the agent prevents degradation of IκB.
- 35. (Original) The method of claim 21, wherein the agent is a proteasome inhibitor.
- 36. (Original) The method of claim 35, wherein the proteasome inhibitor is selected from the group consisting of PS-341, MG-262 and MG-132.
- 37. (Original) The method of claim 21, wherein the agent is an inhibitor of an Inhibitor of Apoptosis (IAP) protein.
- 38. (Original) The method of claim 37, wherein the inhibitor is SMAC or a SMAC mimetic.
- 39. (Original) The method of claim 21, wherein the cancer cell is a colon cancer cell or a pancreatic cancer cell.
- 40. (Original) The method of claim 21, wherein the agent is an antagonist of PAK1.
- 41. (Original) The method of claim 21, wherein the agent is an antagonist of a polypeptide selected from the group consisting of UbcH10, nsurf and JIK.
 - 42. (Original) The method of claim 21, wherein the agent is a siRNA.
- 43. (Original) A physiological composition comprising, a therapeutically effective amount of
 - i. an anti-DR4 or anti-DR5 affinity agent agonist; and

- ii. an apoptosis-inducing agent.
- 44. (Original) The physiological composition of claim 43, wherein the agonist is an anti-DR-5 antibody.
- 45. (Original) The physiological composition of claim 44, wherein the anti-DR5 antibody has the binding specificity of an antibody comprising a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35.
- 46. (Original) The physiological composition of claim 45, wherein the anti-DR5 antibody comprises a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35.
- 47. (Original) The physiological composition of claim 46, wherein the anti-DR5 antibody is Antibody A (ATCC Deposit No. ____).
- 48. (Original) The physiological composition of claim 43, wherein the agonist is an anti-DR4 antibody.
- 49. (Original) The physiological composition of claim 43, wherein the cell is contacted with an anti-DR4 antibody agonist and an anti-DR5 antibody agonist.
- 50. (Original) The physiological composition of claim 43, wherein the agonist is a humanized antibody.
- 51. (Original) The physiological composition of claim 43, wherein the agonist is a single chain antibody.

- 52. (Original) The physiological composition of claim 43, wherein the agent prevents or reduces the expression of BCL-2 or UbcH10.
- 53. (Original) The physiological composition of claim 52, wherein the agent prevents activation of NFκB.
- 54. (Original) The physiological composition of claim 53, wherein the agent prevents degradation of IkB.
- 55. (Original) The physiological composition of claim 43, wherein the agent is a proteasome inhibitor.
- 56. (Original) The physiological composition of claim 43, wherein the agent is an inhibitor of an Inhibitor of Apoptosis (IAP) protein.
- 57. (Original) The physiological composition of claim 56, wherein the inhibitor is SMAC or a SMAC mimetic.
- 58. (Original) The physiological composition of claim 43, wherein the agent is an antagonist of PAK1.
- 59. (Original) The physiological composition of claim 43, wherein the agent is an antagonist of a polypeptide selected from the group consisting of UbcH10, nsurf and JIK.
- 60. (Original) The physiological composition of claim 43, wherein the agent is a siRNA.
- 61. (Currently Amended)An affinity agent with the binding specificity of an antibody comprising a heavy chain variable region comprising the sequence displayed in Figure

24 (SEQ ID NO:4) or Figure 35 (SEQ ID NO:8) and a light chain variable region as displayed in Figure 25 (SEQ ID NO:5) or Figure 35 (SEQ ID NO:10).

- 62. (Currently Amended) The affinity agent of claim 62 61, which is an antibody comprising a heavy chain variable region comprising the sequence displayed in Figure 24 (SEQ ID NO:4) or Figure 35 (SEQ ID NO:8) and a light chain variable region as displayed in Figure 25 (SEQ ID NO:5) or Figure 35 (SEQ ID NO:10).
- 63. (Currently Amended) An isolated cell that expresses an antibody of claim 62 with the binding specificity of an antibody comprising a heavy chain variable region comprising the sequence displayed in Figure 24 (SEQ ID NO:4) or Figure 35 (SEQ ID NO:8) and a light chain variable region as displayed in Figure 25 (SEQ ID NO:5) or Figure 35 (SEQ ID NO:10).
- 64. (Original) A method of inducing apoptosis in a cancer cell, the method comprising contacting the cell with an affinity agent with the binding specificity of an antibody comprising a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35.
 - 65. (New) The affinity of claim 61, wherein the affinity agent is an antibody.
- 66. (New) The affinity agent of claim 65, wherein the antibody is a monoclonal antibody.
- 67. (New) The affinity agent of claim 65, wherein the antibody is a humanized antibody.

- 68. (New) The affinity agent of claim 65, wherein the antibody comprises the complementarity determining regions of the heavy variable region (SEQ ID NO:8) and light variable region (SEQ ID NO:10) of Figure 35.
- 69. (New) The affinity agent of claim 65, wherein the antibody comprises the complementarity determining regions of the heavy variable region displayed in Figure 24 (SEQ ID NO:4) and the light variable region displayed in Figure 25 (SEQ ID NO:5).
- 70. (New) The cell of claim 63, wherein the antibody comprises the complementarity determining regions of the heavy variable region (SEQ ID NO:8) and light variable region (SEQ ID NO:10) of Figure 35.
- 71. (New) The cell of claim 63, wherein the antibody comprises the complementarity determining regions (CDRs) of the heavy variable region displayed in Figure 24 (SEQ ID NO:4) and the light variable region displayed in Figure 25 (SEQ ID NO:5).
- 72. (New) The cell of claim 63, wherein the antibody is a humanized antibody.
- 73. (New) An isolated antibody comprising a complementarity determining region from SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:10.
- 74. (New) An isolated cell that expresses an antibody comprising a complementarity determining region from SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:5 or SEQ ID NO:10.